SARS-CoV-2

The new approach successfully differentiates between antibodies against influenza and those attacking SARS-CoV-2, the virus that causes COVID-19.

Almost all post-COVID neuropathy is linked to a potentially treatable immune dysfunction.

No Omicron immunity without a booster.

The knowledge could help us to reduce the threat to humans of infectious diseases.

Findings could lead to the development of more effective vaccines and antibody treatments.

Mathematical simulations show the new approach may offer faster, cheaper, and more accurate detection.

'Humanized' mice offer a clue.

The new strategy also promises protection against future SARS-CoV-2 variants.

Infant Immune Systems are stronger than you think

Having asthma confers some degree of protection against COVID-19.

Infection plus vaccination yields better antibodies against COVID-19 variants

It could be given to patients whose infection status is unknown or even for a dental check-up when masks need to be removed to reduce the likelihood of passing the virus to caregivers.